NeuroSense Therapeutics (NeuroSense Therapeutics) Price-to-Operating-Cash-Flow : (As of Jun. 01, 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-06-01), NeuroSense Therapeutics's share price is $1.0774. NeuroSense Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, NeuroSense Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for NeuroSense Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

NRSN's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 25.32
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

NeuroSense Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -113.20% per year.

During the past 5 years, NeuroSense Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -113.20% per year. The lowest was -131.70% per year. And the median was -122.45% per year.

NeuroSense Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for NeuroSense Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Price-to-Operating-Cash-Flow Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of NeuroSense Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, NeuroSense Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Price-to-Operating-Cash-Flow falls into.

NeuroSense Therapeutics Price-to-Operating-Cash-Flow Calculation

NeuroSense Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.0774	/	0
	=

NeuroSense Therapeutics's Share Price of today is $1.0774.
NeuroSense Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

NeuroSense Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.